Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Phase 1 · ActiveModality: live biotherapeutic (engineered S. epidermidis, topical)
Aliases SE351, ATR-12-351
Target LEKTI (lympho-epithelial Kazal-type related inhibitor); replaces deficient LEKTI to counter dysregulated skin serine protease activity
Partnerships Fred Hutchinson Cancer Center: exclusive worldwide royalty-bearing license to SyMPL minicircle plasmid technology for genetic engineering (filing notes current candidates were engineered without SyMPL)
Indications
Netherton syndrome(Phase 1)
Status note Phase 1b first patient dosed August 2024; initial safety results reported H1 2025. In June 2026 the Company announced it paused enrollment for capital preservation; filing states it may resume development and has developed improved topical formulations and next-generation candidates.
ATR-04
Phase 1 · ActiveModality: live biotherapeutic (engineered S. epidermidis, topical)
Aliases SE484, ATR-04-484
Target IL-36γ (Interleukin-36 gamma) inhibition
Partnerships Fred Hutchinson Cancer Center: exclusive worldwide royalty-bearing license to SyMPL minicircle plasmid technology for genetic engineering (filing notes current candidates were engineered without SyMPL)
Indications
EGFR inhibitor-associated papulopustular rash in cancer patients(Phase 1)
Catalysts
— around Q4 2026
Status note FDA IND clearance August 2024; Fast Track designation September 2024; first patient dosed in Phase 1/2 trial in Q3 2025. Engineered strain SE484 is D-alanine auxotrophic.
ATR-01
Preclinical · ActiveModality: live biotherapeutic
Indications
not disclosed(Preclinical)
Status note Named as one of three lead product candidates; IND-enabling studies ongoing in 2026 per this filing. No indication or target stated.
Per-asset detail extracted from the 10-Q filed 2026-08-12. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.